Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - doxorubicin hydrochloride -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - doxorubicin hydrochloride -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - doxorubicin hydrochloride -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - epirubicin hydrochloride -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - epirubicin hydrochloride -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - daunorubicin hydrochloride - powder for solution for infusion - 20mg

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

hospira nz ltd - daunorubicin hydrochloride 5.35 mg/ml equivalent to 5 mg/ml daunorubicin - solution for injection - 5 mg/ml - active: daunorubicin hydrochloride 5.35 mg/ml equivalent to 5 mg/ml daunorubicin excipient: sodium chloride water for injection

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - doxorubicin hydrochloride 2 mg/ml - solution for injection - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - doxorubicin has produced significant therapeutic responses in a number of solid tumours and haematologic malignancies, and is commonly used in the treatment of the following tumours: · carcinoma of the breast · carcinoma of the lung · carcinoma of the ovary · transitional bladder cell cancer · neuroblastoma · wilms' tumour · soft tissue sarcomas · osteosarcoma · acute lymphocytic - lymphoblastic leukaemia · acute myelogenous leukaemia · non-hodgkin's lymphoma · hodgkin's disease doxorubicin has also shown antitumour activity in the following adult and paediatric malignancies: · carcinoma of the thyroid · carcinoma of the endometrium · carcinoma of the head and neck · carcinoma of the stomach · primary hepatocellular carcinoma · non-seminomatous carcinoma of the testis · carcinoma of the prostate · ewing's sarcoma · rhabdomyosarcoma · multiple myeloma · chronic leukaemias